At a glance
- Company
- Regentis Biomaterials Ltd
- Ticker
- NYSE American: RGNT
- Announcement
- Expansion
- Location
- Milan, Italy
Key figures
- Planned start of European surgeon training
- third quarter of 2026
- Annual U.S. cartilage knee repair cases cited
- approximately 470,000
Products and programs
Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
To view the full press release, visit https://ibn.fm/QOWWK
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Regentis Biomaterials says it plans to start hands-on training for European orthopedic surgeons in the third quarter of 2026, ahead of a broader commercial rollout of GelrinC. The initial program is expected to take place at Humanitas Research Hospital in Milan, with further sessions planned elsewhere in Europe. The company says its Centers of Excellence network will support surgeon education, clinical guidance and knowledge sharing. GelrinC is a cell-free implant for knee cartilage repair, designed for a ready-to-use, single-step procedure. Regentis describes the training as part of its European commercialization strategy and says greater physician familiarity may support use as the product enters broader clinical practice. The company also cites approximately 470,000 annual U.S. cases for cartilage knee repair, where it says no off-the-shelf treatment is available.
Key takeaways
- Surgeon training activities in Europe are planned to begin in the third quarter of 2026.
- The first session is expected at Humanitas Research Hospital in Milan, with more sessions planned across Europe.
- Regentis says a Centers of Excellence network will support education, clinical guidance and knowledge sharing.
- GelrinC is described as a cell-free implant for single-step knee cartilage repair.
SEC filings
Earlier from Regentis Biomaterials
- Regentis Biomaterials (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
- Regentis Biomaterials (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
- Regentis Biomaterials (NYSE American: RGNT) Is ‘One to Watch’
